| PAH | Controls | p-value | |
| Subjects n | 16 | 18 | |
| Age years | 56±9 | 51±15 | 0.25 |
| Male | 25 | 66 | 0.02 |
| Height cm | 166±11 | 168±11 | 0.65 |
| Weight kg | 77±19 | 75±15 | 0.74 |
| Body mass index kg·m−2 | 27.7±5.6 | 26.4±4.4 | 0.48 |
| Body surface area m2 | 1.87±0.28 | 1.86±0.23 | 0.90 |
| Aetiology | |||
| Idiopathic PAH | 6 (38) | ||
| Scleroderma PAH | 9 (56) | ||
| Portopulmonary hypertension | 1 (16) | ||
| Therapy | |||
| Endothelin receptor antagonist | 75 | ||
| Phosphodiesterase-5 inhibitor | 56 | ||
| Prostanoid | 19 | ||
| Combination therapy | 44 | ||
| NYHA functional class | 2.4±0.7 | ||
| I/II/III/IV n | 2/6/7/1 | ||
| 6MWD m | 410±149 | ||
| V′O2peak mL·min−1·kg−1 | 16.2±7.2 | ||
| Invasive pulmonary haemodynamics# | |||
| Systolic PAP mmHg | 73±17 | ||
| Diastolic PAP mmHg | 27±9 | ||
| Mean PAP mmHg | 46±11 | ||
| PAWP mmHg | 8±2 | ||
| RAP mmHg | 9±5 |
Data are presented as mean±sd, % or n (%), unless otherwise stated. PAH: pulmonary arterial hypertension; NYHA: New York Heart Association; 6MWD: 6-min walk distance; V′O2peak: peak oxygen uptake; PAP: pulmonary artery pressure; PAWP: pulmonary artery wedge pressure; RAP: right atrial pressure. #: invasive haemodynamics obtained at time of initial diagnostic catheterisation.